{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:42:54Z","timestamp":1789674174052,"version":"4.0.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40291-025-00789-3","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T03:02:32Z","timestamp":1749265352000},"page":"591-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current Methods in Clinical Alzheimer\u2019s Disease Research and Diagnosis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-6409","authenticated-orcid":false,"given":"Eleftheria","family":"Kodosaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-6405","authenticated-orcid":false,"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"3","key":"789_CR1","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/S2666-7568(23)00022-3","volume":"4","author":"CK Suemoto","year":"2023","unstructured":"Suemoto CK, Leite RE. Autopsy studies are key to identifying dementia cause. Lancet Healthy Longevity. 2023;4(3):e94\u20135.","journal-title":"Lancet Healthy Longevity."},{"issue":"3","key":"789_CR2","first-page":"195","volume":"9","author":"D Cvetkovi\u0107-Do\u017ei\u0107","year":"2001","unstructured":"Cvetkovi\u0107-Do\u017ei\u0107 D, Skender-Gazibara M, Do\u017ei\u0107 S. Neuropathological hallmarks of Alzheimer\u2019s disease. Arch Oncol. 2001;9(3):195\u20139.","journal-title":"Arch Oncol"},{"issue":"10","key":"789_CR3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/NEN.0b013e31822e8ae9","volume":"70","author":"KS SantaCruz","year":"2011","unstructured":"SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL. Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the nun study and the adult changes in thought study. J Neuropathol Exp Neurol. 2011;70(10):832\u201340.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"789_CR4","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.14336\/AD.2021.0526","volume":"12","author":"S Tetsuka","year":"2021","unstructured":"Tetsuka S. Depression and dementia in older adults: a neuropsychological review. Aging Dis. 2021;12(8):1920.","journal-title":"Aging Dis"},{"issue":"1","key":"789_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/09540261.2019.1682529","volume":"32","author":"T Pradeep","year":"2020","unstructured":"Pradeep T, Bray MJ, Arun S, Richey LN, Jahed S, Bryant BR, et al. History of traumatic brain injury interferes with accurate diagnosis of Alzheimer\u2019s dementia: a nation-wide case-control study. Int Rev Psychiatry. 2020;32(1):61\u201370.","journal-title":"Int Rev Psychiatry"},{"issue":"1","key":"789_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40035-023-00364-y","volume":"12","author":"L Xu","year":"2023","unstructured":"Xu L, Liu R, Qin Y, Wang T. Brain metabolism in Alzheimer\u2019s disease: biological mechanisms of exercise. Trans Neurodegeneration. 2023;12(1):33.","journal-title":"Trans Neurodegeneration."},{"issue":"3","key":"789_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/biom8030093","volume":"8","author":"SSR Nirzhor","year":"2018","unstructured":"Nirzhor SSR, Khan RI, Neelotpol S. The biology of glial cells and their complex roles in Alzheimer\u2019s disease: new opportunities in therapy. Biomolecules. 2018;8(3):93.","journal-title":"Biomolecules"},{"issue":"1700","key":"789_CR8","doi-asserted-by":"publisher","first-page":"20150429","DOI":"10.1098\/rstb.2015.0429","volume":"371","author":"MA Busche","year":"2016","unstructured":"Busche MA, Konnerth A. Impairments of neural circuit function in Alzheimer\u2019s disease. Philosophical Trans R Soc B. 2016;371(1700):20150429.","journal-title":"Philosophical Trans R Soc B."},{"issue":"5","key":"789_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology"},{"issue":"5","key":"789_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr","year":"2009","unstructured":"Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease. Brain. 2009;132(5):1355\u201365.","journal-title":"Brain"},{"issue":"8","key":"789_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135365","volume":"10","author":"RC Hendrickson","year":"2015","unstructured":"Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, et al. High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer\u2019s disease in human cerebrospinal fluid. PLoS ONE. 2015;10(8): e0135365.","journal-title":"PLoS ONE"},{"issue":"6","key":"789_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199356","volume":"16","author":"JM Bader","year":"2020","unstructured":"Bader JM, Geyer PE, M\u00fcller JB, Strauss MT, Koch M, Leypoldt F, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease. Mol Syst Biol. 2020;16(6): e9356.","journal-title":"Mol Syst Biol"},{"issue":"12","key":"789_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14737159.2023.2289553","volume":"23","author":"E Kodosaki","year":"2023","unstructured":"Kodosaki E, Zetterberg H, Heslegrave A. Validating blood tests as a possible routine diagnostic assay of Alzheimer\u2019s disease. Expert Rev Mol Diagn. 2023;23(12):1153\u201365.","journal-title":"Expert Rev Mol Diagn"},{"issue":"12","key":"789_CR14","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"789_CR15","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/alz.12316","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson O, Batrla R, Brix B, Carrillo MC, Corradini V, Edelmayer RM, et al. The Alzheimer\u2019s association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimers Dement. 2021;17(9):1575\u201382.","journal-title":"Alzheimers Dement"},{"key":"789_CR16","doi-asserted-by":"crossref","unstructured":"Morbelli S, Bauckneht M. Amyloid PET imaging: standardization and integration with other Alzheimer\u2019s disease biomarkers. Biomarkers for Alzheimer\u2019s Dis Drug Dev. 2018:203-12.","DOI":"10.1007\/978-1-4939-7704-8_13"},{"key":"789_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.061177","volume":"18","author":"V Dore","year":"2022","unstructured":"Dore V, Bullich S, Bohorquez SS, Leuzy A, Shimada H, Rowe C, et al. CenTauRz: a standardized quantification of tau PET scans. Alzheimers Dement. 2022;18: e061177.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"789_CR18","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/j.jalz.2013.05.1769","volume":"9","author":"MW Weiner","year":"2013","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer\u2019s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111\u201394.","journal-title":"Alzheimers Dement"},{"key":"789_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.751897","volume":"13","author":"R Ni","year":"2022","unstructured":"Ni R, Nitsch RM. Recent developments in positron emission tomography tracers for proteinopathies imaging in dementia. Front Aging Neurosci. 2022;13: 751897.","journal-title":"Front Aging Neurosci."},{"issue":"13","key":"789_CR20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394.","journal-title":"JAMA"},{"issue":"4","key":"789_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","volume":"20","author":"J Therriault","year":"2024","unstructured":"Therriault J, Schindler SE, Salvad\u00f3 G, Pascoal TA, Benedet AL, Ashton NJ, et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol. 2024;20(4):232\u201344.","journal-title":"Nat Rev Neurol"},{"key":"789_CR22","doi-asserted-by":"crossref","unstructured":"Mavrina E, Kimble L, Waury K, Gogishvili D, G\u00f3mez de San Jos\u00e9 N, Das S, et al. Multi-omics interdisciplinary research integration to accelerate dementia biomarker development (MIRIADE). Front Neurol. 2022;13:890638.","DOI":"10.3389\/fneur.2022.890638"},{"issue":"3","key":"789_CR23","volume":"15","author":"C Giangrande","year":"2023","unstructured":"Giangrande C, Delatour V, Andreasson U, Blennow K, Gobom J, Zetterberg H. Harmonization and standardization of biofluid-based biomarker measurements for AT (N) classification in Alzheimer\u2019s disease. Alzheimers Dement. 2023;15(3): e12465.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"789_CR24","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jproteome.9b00258","volume":"18","author":"P San Segundo-Acosta","year":"2019","unstructured":"San Segundo-Acosta P, Montero-Calle A, Fuentes M, R\u00e1bano A, Villalba M, Barderas R. Identification of Alzheimer\u2019s disease autoantibodies and their target biomarkers by phage microarrays. J Proteome Res. 2019;18(7):2940\u201353.","journal-title":"J Proteome Res"},{"issue":"1","key":"789_CR25","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1038\/s41598-019-40976-x","volume":"9","author":"K-Y Sim","year":"2019","unstructured":"Sim K-Y, Park S-H, Choi KY, Park JE, Lee JS, Kim BC, et al. High-throughput epitope profiling of antibodies in the plasma of Alzheimer\u2019s disease patients using random peptide microarrays. Sci Rep. 2019;9(1):4587.","journal-title":"Sci Rep"},{"issue":"11","key":"789_CR26","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"789_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-023-00510-8","volume":"11","author":"Y Li","year":"2023","unstructured":"Li Y, Tam WW, Yu Y, Zhuo Z, Xue Z, Tsang C, et al. The application of Aptamer in biomarker discovery. Biomarker Res. 2023;11(1):70.","journal-title":"Biomarker Res."},{"key":"789_CR28","doi-asserted-by":"crossref","unstructured":"McKeague M, DeRosa MC. Challenges and opportunities for small molecule aptamer development. Journal of nucleic acids. 2012;2012.","DOI":"10.1155\/2012\/748913"},{"issue":"1","key":"789_CR29","doi-asserted-by":"publisher","first-page":"14248","DOI":"10.1038\/s41598-017-14755-5","volume":"7","author":"J Candia","year":"2017","unstructured":"Candia J, Cheung F, Kotliarov Y, Fantoni G, Sellers B, Griesman T, et al. Assessment of variability in the SOMAscan assay. Sci Rep. 2017;7(1):14248.","journal-title":"Sci Rep"},{"issue":"6","key":"789_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","volume":"10","author":"M Sattlecker","year":"2014","unstructured":"Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, et al. Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 2014;10(6):724\u201334.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"789_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JAD-220399","volume":"89","author":"J Timsina","year":"2022","unstructured":"Timsina J, Gomez-Fonseca D, Wang L, Do A, Western D, Alvarez I, et al. Comparative analysis of Alzheimer\u2019s disease cerebrospinal fluid biomarkers measurement by multiplex SOMAscan platform and immunoassay-based approach 1. J Alzheimers Dis. 2022;89(1):193\u2013207.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"789_CR32","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jalz.2019.06.4951","volume":"15","author":"L Shi","year":"2019","unstructured":"Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, et al. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimers Dement. 2019;15(11):1478\u201388.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"789_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212261","volume":"14","author":"E Begic","year":"2019","unstructured":"Begic E, Hadzidedic S, Kulaglic A, Ramic-Brkic B, Begic Z, Causevic M. SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer\u2019s dementia patients. PLoS ONE. 2019;14(2): e0212261.","journal-title":"PLoS ONE"},{"issue":"18","key":"789_CR34","doi-asserted-by":"publisher","first-page":"7416","DOI":"10.1039\/C5AY00650C","volume":"7","author":"B G\u00fclbakan","year":"2015","unstructured":"G\u00fclbakan B. Oligonucleotide aptamers: emerging affinity probes for bioanalytical mass spectrometry and biomarker discovery. Anal Methods. 2015;7(18):7416\u201330.","journal-title":"Anal Methods"},{"key":"789_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.659760","volume":"9","author":"J Huang","year":"2021","unstructured":"Huang J, Chen X, Fu X, Li Z, Huang Y, Liang C. Advances in aptamer-based biomarker discovery. Front Cell Dev Biol. 2021;9: 659760.","journal-title":"Front Cell Dev Biol."},{"issue":"7","key":"789_CR36","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3390\/biomedicines10071606","volume":"10","author":"A Davydova","year":"2022","unstructured":"Davydova A, Vorobyeva M. Aptamer-based biosensors for the colorimetric detection of blood biomarkers: paving the way to clinical laboratory testing. Biomedicines. 2022;10(7):1606.","journal-title":"Biomedicines."},{"issue":"1","key":"789_CR37","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1038\/s41467-023-43575-7","volume":"14","author":"J You","year":"2023","unstructured":"You J, Guo Y, Zhang Y, Kang J-J, Wang L-B, Feng J-F, et al. Plasma proteomic profiles predict individual future health risk. Nat Commun. 2023;14(1):7817.","journal-title":"Nat Commun"},{"issue":"7","key":"789_CR38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1515\/cclm-2022-1181","volume":"61","author":"U Andreasson","year":"2023","unstructured":"Andreasson U, Gobom J, Delatour V, Auclair G, Noam Y, Lee S, et al. Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood. Clin Chem Lab Med (CCLM). 2023;61(7):1245\u201354.","journal-title":"Clin Chem Lab Med (CCLM)."},{"issue":"13\u201314","key":"789_CR39","doi-asserted-by":"publisher","first-page":"2100170","DOI":"10.1002\/pmic.202100170","volume":"22","author":"DE Haslam","year":"2022","unstructured":"Haslam DE, Li J, Dillon ST, Gu X, Cao Y, Zeleznik OA, et al. Stability and reproducibility of proteomic profiles in epidemiological studies: comparing the Olink and SOMAscan platforms. Proteomics. 2022;22(13\u201314):2100170.","journal-title":"Proteomics"},{"issue":"1","key":"789_CR40","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","volume":"14","author":"W Feng","year":"2023","unstructured":"Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14(1):7238.","journal-title":"Nat Commun"},{"key":"789_CR41","doi-asserted-by":"crossref","unstructured":"Abe K, Beer JC, Nguyen T, Ariyapala IS, Holmes TH, Feng W, et al. Cross-platform comparison of highly sensitive immunoassays for inflammatory markers in a COVID-19 Cohort. J Immunol. 2023.","DOI":"10.1101\/2023.10.24.563866"},{"issue":"8","key":"789_CR42","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.neurobiolaging.2007.02.016","volume":"29","author":"S Engelborghs","year":"2008","unstructured":"Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29(8):1143\u201359.","journal-title":"Neurobiol Aging"},{"key":"789_CR43","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Initiative AsDN, Minthon L, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85(14):1240-9.","DOI":"10.1212\/WNL.0000000000001991"},{"issue":"5","key":"789_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1515\/CCLM.2010.131","volume":"48","author":"N Mattsson","year":"2010","unstructured":"Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: united we stand, divided we fall. Clin Chem Lab Med. 2010;48(5):603\u20137.","journal-title":"Clin Chem Lab Med"},{"issue":"19","key":"789_CR45","doi-asserted-by":"publisher","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","volume":"99","author":"A Rosenberg","year":"2022","unstructured":"Rosenberg A, \u00d6hlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryd\u00e9n M, et al. \u03b2-Amyloid, tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. Neurology. 2022;99(19):e2102\u201313.","journal-title":"Neurology"},{"issue":"2","key":"789_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med (CCLM). 2022;60(2):207\u201319.","journal-title":"Clin Chem Lab Med (CCLM)."},{"key":"789_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leit\u00e3o","year":"2019","unstructured":"Leit\u00e3o MJ, Silva-Sp\u00ednola A, Santana I, Olmedo V, Nadal A, Le Bastard N, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy. 2019;11:1\u201312.","journal-title":"Alzheimer's Res Therapy."},{"issue":"1","key":"789_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/alz.12000","volume":"16","author":"J Kaplow","year":"2020","unstructured":"Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham C, et al. Concordance of Lumipulse cerebrospinal fluid t-tau\/A\u03b242 ratio with amyloid PET status. Alzheimers Dement. 2020;16(1):144\u201352.","journal-title":"Alzheimers Dement"},{"key":"789_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.604119","volume":"13","author":"F Dakterzada","year":"2021","unstructured":"Dakterzada F, L\u00f3pez-Ortega R, Arias A, Riba-Llena I, Ruiz-Juli\u00e1n M, Huerto R, et al. Assessment of the concordance and diagnostic accuracy between Elecsys and Lumipulse fully automated platforms and Innotest. Front Aging Neurosci. 2021;13: 604119.","journal-title":"Front Aging Neurosci."},{"issue":"1","key":"789_CR50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2017.06.2265","volume":"12","author":"O Hansson","year":"2020","unstructured":"Hansson O, Rutz S, Zetterberg H, Bauer E, H\u00e4hl T, Manuilova E, et al. Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF. Alzheimer\u2019s Dementia. 2020;12(1): e12137.","journal-title":"Alzheimer's Dementia"},{"key":"789_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-020-03225-5","volume":"19","author":"JS Bolton","year":"2020","unstructured":"Bolton JS, Chaudhury S, Dutta S, Gregory S, Locke E, Pierson T, et al. Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination. Malar J. 2020;19:1\u201313.","journal-title":"Malar J"},{"issue":"2","key":"789_CR52","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1515\/cclm-2022-0516","volume":"61","author":"K Blennow","year":"2023","unstructured":"Blennow K, Stomrud E, Zetterberg H, Borlinghaus N, Corradini V, Manuilova E, et al. Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer\u2019s disease. Clin Chem Lab Med (CCLM). 2023;61(2):234\u201344.","journal-title":"Clin Chem Lab Med (CCLM)."},{"issue":"1","key":"789_CR53","first-page":"698","volume":"10","author":"LM Shaw","year":"2018","unstructured":"Shaw LM, Waligorska T, Fields L, Korecka M, Figurski M, Trojanowski JQ, et al. Derivation of cutoffs for the Elecsys\u00ae amyloid \u03b2 (1\u201342) assay in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2018;10(1):698\u2013705.","journal-title":"Alzheimer's Dementia"},{"issue":"5","key":"789_CR54","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack Jr","year":"2023","unstructured":"Jack CR Jr, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, Schwarz CG, Lowe VJ, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023;146(5):2029\u201344.","journal-title":"Brain"},{"issue":"11","key":"789_CR55","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382.","journal-title":"JAMA Neurol"},{"issue":"4","key":"789_CR56","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601.","journal-title":"Brain"},{"key":"789_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2021.113789","volume":"197","author":"J Zamanian","year":"2022","unstructured":"Zamanian J, Khoshbin Z, Abnous K, Taghdisi SM, Hosseinzadeh H, Danesh NM. Current progress in aptamer-based sensing tools for ultra-low level monitoring of Alzheimer\u2019s disease biomarkers. Biosens Bioelectron. 2022;197: 113789.","journal-title":"Biosens Bioelectron"},{"key":"789_CR58","unstructured":"Available from: https:\/\/c2n.com\/news-releases\/cn-diagnostics-precivity-related-blood-biomarkers-shown-to-improve-diagnostic-accuracy-and-future-risk-prediction-of-alzheimers-disease-in-two-studies-presented-at-adpd-2023."},{"issue":"4","key":"789_CR59","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ymeth.2012.03.023","volume":"56","author":"J-H Kang","year":"2012","unstructured":"Kang J-H, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer\u2019s disease. Methods. 2012;56(4):484\u201393.","journal-title":"Methods"},{"key":"789_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.716686","volume":"12","author":"EO Hansen","year":"2021","unstructured":"Hansen EO, Dias NS, Burgos ICB, Costa MV, Carvalho AT, Teixeira AL, et al. Millipore xMap\u00ae Luminex (HATMAG-68K): An accurate and cost-effective method for evaluating Alzheimer\u2019s biomarkers in cerebrospinal fluid. Front Psych. 2021;12: 716686.","journal-title":"Front Psych"},{"issue":"1","key":"789_CR61","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1038\/s41598-023-29704-8","volume":"13","author":"M Truffi","year":"2023","unstructured":"Truffi M, Garofalo M, Ricciardi A, Cotta Ramusino M, Perini G, Scaranzin S, et al. Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study. Sci Rep. 2023;13(1):4041.","journal-title":"Sci Rep"},{"key":"789_CR62","doi-asserted-by":"crossref","unstructured":"Soelter TM, Whitlock JH, Williams AS, Hardigan AA, Lasseigne BN. Nucleic acid liquid biopsies in Alzheimer\u2019s disease: Current state, challenges, and opportunities. Heliyon. 2022.","DOI":"10.20944\/preprints202108.0518.v2"},{"issue":"3","key":"789_CR63","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.cell.2016.06.041","volume":"166","author":"U Kusebauch","year":"2016","unstructured":"Kusebauch U, Campbell DS, Deutsch EW, Chu CS, Spicer DA, Brusniak M-Y, et al. Human SRMAtlas: a resource of targeted assays to quantify the complete human proteome. Cell. 2016;166(3):766\u201378.","journal-title":"Cell"},{"issue":"2","key":"789_CR64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/jnc.15465","volume":"159","author":"M Korecka","year":"2021","unstructured":"Korecka M, Shaw LM. Mass spectrometry-based methods for robust measurement of Alzheimer\u2019s disease biomarkers in biological fluids. J Neurochem. 2021;159(2):211\u201333.","journal-title":"J Neurochem"},{"issue":"1","key":"789_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41597-023-02158-3","volume":"10","author":"CM Watson","year":"2023","unstructured":"Watson CM, Dammer EB, Ping L, Duong DM, Modeste E, Carter EK, et al. Quantitative mass spectrometry analysis of cerebrospinal fluid protein biomarkers in Alzheimer\u2019s disease. Scientific Data. 2023;10(1):1\u201314.","journal-title":"Scientific Data."},{"issue":"5","key":"789_CR66","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/bmc.3084","volume":"28","author":"N Zhou","year":"2014","unstructured":"Zhou N, Wang J, Yu Y, Shi J, Li X, Xu B, et al. Mass spectrum analysis of serum biomarker proteins from patients with schizophrenia. Biomed Chromatogr. 2014;28(5):654\u20139.","journal-title":"Biomed Chromatogr"},{"issue":"1","key":"789_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-020-09285-8","volume":"17","author":"M Zhou","year":"2020","unstructured":"Zhou M, Haque RU, Dammer EB, Duong DM, Ping L, Johnson EC, et al. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer\u2019s disease. Clin Proteomics. 2020;17(1):1\u201314.","journal-title":"Clin Proteomics"},{"issue":"11","key":"789_CR68","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/brain\/awl279","volume":"129","author":"A Hye","year":"2006","unstructured":"Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers H, et al. Proteome-based plasma biomarkers for Alzheimer\u2019s disease. Brain. 2006;129(11):3042\u201350.","journal-title":"Brain"},{"key":"789_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","volume":"519","author":"KM Kirmess","year":"2021","unstructured":"Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, et al. The PrecivityAD\u2122 test: Accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267\u201375.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"789_CR70","first-page":"79","volume":"105","author":"J Anderson","year":"2022","unstructured":"Anderson J, Pierce C. PrecivityAD for diagnosis of Alzheimer disease. Am Fam Physician. 2022;105(1):79\u201381.","journal-title":"Am Fam Physician"},{"issue":"16","key":"789_CR71","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/diagnostics14161739","volume":"14","author":"SM Eastwood","year":"2024","unstructured":"Eastwood SM, Meyer MR, Kirmess KM, Wente-Roth TL, Irvin F, Holubasch MS, et al. PrecivityAD2\u2122 blood test: analytical validation of an LC-MS\/MS assay for quantifying plasma phospho-tau217 and non-phospho-tau217 peptide concentrations that are used with plasma amyloid-\u03b242\/40 in a multianalyte assay with algorithmic analysis for detecting brain amyloid pathology. Diagnostics. 2024;14(16):1739.","journal-title":"Diagnostics"},{"issue":"3","key":"789_CR72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/pop.2023.0309","volume":"27","author":"WJ Canestaro","year":"2024","unstructured":"Canestaro WJ, Bateman RJ, Holtzman DM, Monane M, Braunstein JB. Use of a blood biomarker test improves economic utility in the evaluation of older patients presenting with cognitive impairment. Popul Health Manag. 2024;27(3):174\u201384.","journal-title":"Popul Health Manag"},{"issue":"1","key":"789_CR73","first-page":"5","volume":"1","author":"JM Yeo","year":"2015","unstructured":"Yeo JM, Waddell B, Khan Z, Pal S. A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2015;1(1):5\u201313.","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"789_CR74","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3233\/JAD-200079","volume":"76","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Kim YJ, Kim HJ, Jang H, Kim Y, et al. Head-to-head comparison of 18F-florbetaben and 18F-flutemetamol in the cortical and striatal regions. J Alzheimers Dis. 2020;76(1):281\u201390.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"789_CR75","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch\u00f6ll M, Strandberg O, et al. Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151\u201362.","journal-title":"JAMA"},{"key":"789_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.arr.2016.02.003","volume":"30","author":"T Kato","year":"2016","unstructured":"Kato T, Inui Y, Nakamura A, Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev. 2016;30:73\u201384.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"789_CR77","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2967\/jnumed.122.264256","volume":"64","author":"C Boccalini","year":"2023","unstructured":"Boccalini C, Peretti DE, Ribaldi F, Scheffler M, Stampacchia S, Tomczyk S, et al. Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting. J Nucl Med. 2023;64(2):266\u201373.","journal-title":"J Nucl Med"},{"issue":"1","key":"789_CR78","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/alz.13529","volume":"20","author":"J Alber","year":"2024","unstructured":"Alber J, Bouwman F, den Haan J, Rissman RA, De Groef L, Koronyo-Hamaoui M, et al. Retina pathology as a target for biomarkers for Alzheimer\u2019s disease: Current status, ophthalmopathological background, challenges, and future directions. Alzheimers Dement. 2024;20(1):728\u201340.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"789_CR79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40478-024-01868-y","volume":"12","author":"X Du","year":"2024","unstructured":"Du X, Park J, Zhao R, Smith RT, Koronyo Y, Koronyo-Hamaoui M, et al. Hyperspectral retinal imaging in Alzheimer\u2019s disease and age-related macular degeneration: a review. Acta Neuropathol Commun. 2024;12(1):157.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"789_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-024-01668-5","volume":"17","author":"S Ravichandran","year":"2025","unstructured":"Ravichandran S, Snyder PJ, Alber J, Murchison CF, Chaby LE, Jeromin A, et al. Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy. 2025;17(1):19.","journal-title":"Alzheimer's Res Therapy."},{"key":"789_CR81","doi-asserted-by":"crossref","unstructured":"Bader I, Groot C, Tan HS, Milongo J-MA, Haan Jd, Verberk IM, et al. Rationale and design of the BeyeOMARKER study: prospective evaluation of blood-and eye-based biomarkers for early detection of Alzheimer\u2019s disease pathology in the eye clinic. Alzheimer's Res Therapy. 2024;16(1):190.","DOI":"10.1186\/s13195-024-01545-1"},{"issue":"6","key":"789_CR82","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"key":"789_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RY, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimer\u2019s Res Therapy. 2021;13:1\u201314.","journal-title":"Alzheimer's Res Therapy."},{"key":"789_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-021-01111-z","volume":"19","author":"L Zhang","year":"2021","unstructured":"Zhang L, Du X, Su Y, Niu S, Li Y, Liang X, et al. Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay. J Nanobiotechnol. 2021;19:1\u201317.","journal-title":"J Nanobiotechnol"},{"key":"789_CR85","doi-asserted-by":"crossref","unstructured":"Zhang L, Su Y, Liang X, Cao K, Luo Q, Luo H. Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer\u2019s disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay. Nano Research. 2023:1-11.","DOI":"10.1007\/s12274-022-5354-4"},{"issue":"11","key":"789_CR86","doi-asserted-by":"publisher","first-page":"13325","DOI":"10.1021\/acsnano.9b06571","volume":"13","author":"LC Brazaca","year":"2019","unstructured":"Brazaca LC, Moreto JR, Mart\u00edn A, Tehrani F, Wang J, Zucolotto V. Colorimetric paper-based immunosensor for simultaneous determination of fetuin B and clusterin toward early Alzheimer\u2019s diagnosis. ACS Nano. 2019;13(11):13325\u201332.","journal-title":"ACS Nano"},{"key":"789_CR87","doi-asserted-by":"crossref","unstructured":"Kiani L. Finger-prick blood test for Alzheimer disease. Nat Rev Neurol. 2023:1-.","DOI":"10.1038\/s41582-023-00857-4"},{"issue":"1","key":"789_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14259","volume":"21","author":"H Huber","year":"2025","unstructured":"Huber H, Cantoni V, Altomare D, Gr\u00f6tschel L, Montoliu-Gaya L, Meda F, et al. The detection of GRN mutation carriers by progranulin blood protein levels from finger-stick collection. Alzheimers Dement. 2025;21(1): e14259.","journal-title":"Alzheimers Dement"},{"key":"789_CR89","doi-asserted-by":"crossref","unstructured":"Kolanko MA, Huber H, David MC, Montoliu-Gaya L, Simr\u00e9n J, Blennow K, et al. Quantification of neurofilament light and glial fibrillary acidic protein in finger-prick blood. Brain Communications. 2024;6(3):fcae151.","DOI":"10.1093\/braincomms\/fcae151"},{"issue":"1","key":"789_CR90","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-022-01029-0","volume":"14","author":"K Yamashita","year":"2022","unstructured":"Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, et al. Fully automated and highly specific plasma \u03b2-amyloid immunoassays predict \u03b2-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimer\u2019s Res Therapy. 2022;14(1):86.","journal-title":"Alzheimer's Res Therapy."},{"key":"789_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/alz.064182","volume":"18","author":"DM Weber","year":"2022","unstructured":"Weber DM, Kim JC, Goldman S, Racke MK, Clarke NJ. A new LC-MS\/MS assay for the quantification of A\u03b240 and A\u03b242 in plasma: validation and clinical performance. Alzheimers Dement. 2022;18: e064182.","journal-title":"Alzheimers Dement"},{"key":"789_CR92","doi-asserted-by":"crossref","unstructured":"Ashton NJ, Brum WS, di Molfetta G, Benedet AL, Arslan B, Jonaitis EM, et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimers disease pathology. medRxiv. 2023:2023.07. 11.23292493.","DOI":"10.1101\/2023.07.11.23292493"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00789-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:02:50Z","timestamp":1757966570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00789-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00789-3","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"8 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Henrik Zetterberg has served at scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Eleftheria Kodosaki and Amanda Heslegrave have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation: AJH. Writing (original draft preparation): EK. Writing (review and editing): EK, AJH, HZ. Supervision: AJH, HZ.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}